| Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) | TA961 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | TA962 | | |
| Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) | TA965 | | |
| Ritlecitinib for treating severe alopecia areata in people 12 years and over | TA958 | | |
| Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis | TA959 | | |
| Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) | TA960 | | |
| Ovarian cancer: identifying and managing familial and genetic risk | NG241 | | |
| Momelotinib for treating myelofibrosis-related splenomegaly or symptoms | TA957 | | |
| Suspected sepsis: recognition, diagnosis and early management | NG51 | | |
| Neonatal infection: antibiotics for prevention and treatment | NG195 | | |
| Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management | NG240 | | |
| Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | TA878 | | |
| Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema | TA953 | | |
| Dupilumab for treating moderate to severe prurigo nodularis | TA955 | | |
| Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over | TA956 | | |
| Lung cancer: diagnosis and management | NG122 | | |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA954 | | |
| Vitamin B12 deficiency in over 16s: diagnosis and management | NG239 | | |
| Endoscopic sleeve gastroplasty for obesity | IPG783 | | |
| Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations | TA952 | | |
| Tuberculosis | NG33 | | |
| Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over | TA949 | | |
| Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over | TA950 | | |
| Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer | TA951 | | |
| Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments | TA947 | | |
| Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments | TA948 | | |
| Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) | TA945 | | |
| Caesarean birth | NG192 | | |
| Devices for remote monitoring of Parkinson's disease | DG51 | | |
| Pharyngeal electrical stimulation for neurogenic dysphagia | IPG781 | | |
| Temperature control to improve neurological outcomes after cardiac arrest | IPG782 | | |
| Artificial intelligence (AI)-derived software to help clinical decision making in stroke | DG57 | | |
| Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | TA946 | | |
| Early and locally advanced breast cancer: diagnosis and management | NG101 | | |
| Sebelipase alfa for treating Wolman disease | HST30 | | |
| Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer | TA944 | | |
| Intravascular lithotripsy for calcified arteries in peripheral arterial disease | IPG780 | | |
| Bipolar disorder: assessment and management | CG185 | | |
| Targeted-release budesonide for treating primary IgA nephropathy | TA937 | | |
| Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) | TA940 | | |
| Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) | TA941 | | |
| Empagliflozin for treating chronic kidney disease | TA942 | | |
| Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | TA943 | | |
| Risdiplam for treating spinal muscular atrophy | TA755 | | |
| Middle meningeal artery embolisation for chronic subdural haematomas | IPG779 | | |
| Cardiovascular disease: risk assessment and reduction, including lipid modification | NG238 | | |
| Velmanase alfa for treating alpha-mannosidosis | HST29 | | |
| Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | TA939 | | |
| Acne vulgaris: management | NG198 | | |
| Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) | TA938 | | |
| Secukinumab for treating moderate to severe hidradenitis suppurativa | TA935 | | |
| Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) | TA936 | | |
| Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism | IPG778 | | |
| Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) | TA933 | | |
| Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms | TA934 | | |
| Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) | TA932 | | |
| Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis | IPG777 | | |
| Zanubrutinib for treating chronic lymphocytic leukaemia | TA931 | | |
| Transient loss of consciousness ('blackouts') in over 16s | CG109 | | |
| Hypertension in adults: diagnosis and management | NG136 | | |
| Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management | NG237 | | |
| Biodegradable subacromial spacer insertion for rotator cuff tears | IPG775 | | |
| Extracorporeal carbon dioxide removal for acute respiratory failure | IPG776 | | |
| Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments | TA930 | | |
| Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | CG164 | | |
| Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA929 | | |
| Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine | TA928 | | |
| Jaundice in newborn babies under 28 days | CG98 | | |
| Pneumonia in adults: diagnosis and management | CG191 | | |
| Ranibizumab for treating diabetic macular oedema | TA274 | | |
| Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions | IPG774 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable | TA917 | | |
| Tirzepatide for treating type 2 diabetes | TA924 | | |
| Mirikizumab for treating moderately to severely active ulcerative colitis | TA925 | | |
| Baricitinib for treating severe alopecia areata | TA926 | | |
| Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) | TA923 | | |
| Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia | IPG773 | | |
| Stroke rehabilitation in adults | NG236 | | |
| Rimegepant for treating migraine | TA919 | | |
| Tofacitinib for treating active ankylosing spondylitis | TA920 | | |
| Ruxolitinib for treating polycythaemia vera | TA921 | | |
| Daridorexant for treating long-term insomnia | TA922 | | |
| Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA927 | | |
| Thyroid disease: assessment and management | NG145 | | |
| Bimekizumab for treating axial spondyloarthritis | TA918 | | |
| Pegunigalsidase alfa for treating Fabry disease | TA915 | | |
| Bimekizumab for treating active psoriatic arthritis | TA916 | | |
| Urinary incontinence in neurological disease: assessment and management | CG148 | | |
| Ovarian cancer: recognition and initial management | CG122 | | |
| Suspected cancer: recognition and referral | NG12 | | |
| Suspected neurological conditions: recognition and referral | NG127 | | |
| Hearing loss in adults: assessment and management | NG98 | | |
| Intrapartum care | NG235 | | |
| Acute kidney injury: prevention, detection and management | NG148 | | |
| Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment | IPG772 | | |
| Birch bark extract for treating epidermolysis bullosa | HST28 | | |
| Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency | TA914 | | |
| Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG770 | | |
| Cryotherapy for chronic rhinitis | IPG771 | | |
| Cirrhosis in over 16s: assessment and management | NG50 | | |
| Spinal metastases and metastatic spinal cord compression | NG234 | | |
| Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy | TA913 | | |
| Semaglutide for managing overweight and obesity | TA875 | | |
| Otitis media with effusion in under 12s | NG233 | | |
| Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care | DG56 | | |
| Ectopic pregnancy and miscarriage: diagnosis and initial management | NG126 | | |
| Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease | TA912 | | |
| Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease | IPG769 | | |
| Venous thromboembolic diseases: diagnosis, management and thrombophilia testing | NG158 | | |
| Obesity: identification, assessment and management | CG189 | | |
| Afamelanotide for treating erythropoietic protoporphyria | HST27 | | |
| Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer | TA911 | | |
| KardiaMobile for detecting atrial fibrillation | MTG64 | | |
| Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) | TA910 | | |
| Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer | TA909 | | |
| AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images | DG55 | | |
| Irreversible electroporation for treating prostate cancer | IPG768 | | |
| Rimegepant for preventing migraine | TA906 | | |
| Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy | TA908 | | |
| Oesophago-gastric cancer: assessment and management in adults | NG83 | | |
| Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention | IPG766 | | |
| Radiofrequency denervation for osteoarthritic knee pain | IPG767 | | |
| Deucravacitinib for treating moderate to severe plaque psoriasis | TA907 | | |
| Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option | IPG764 | | |
| Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people | IPG765 | | |
| Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA902 | | |
| Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer | TA903 | | |
| Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer | TA904 | | |
| Upadacitinib for previously treated moderately to severely active Crohn's disease | TA905 | | |
| Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) | TA901 | | |
| Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer | TA898 | | |
| Tixagevimab plus cilgavimab for preventing COVID-19 | TA900 | | |
| FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care | DG48 | | |
| Atopic eczema in under 12s: diagnosis and management | CG57 | | |
| Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma | TA894 | | |
| Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy | TA895 | | |
| Bulevirtide for treating chronic hepatitis D | TA896 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over | TA893 | | |
| Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer | IPG763 | | |
| Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma | TA897 | | |
| Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) | TA899 | | |
| Transperineal biopsy for diagnosing prostate cancer | DG54 | | |
| Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia | TA891 | | |
| Mosunetuzumab for treating relapsed or refractory follicular lymphoma | TA892 | | |
| Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers | DG52 | | |
| MRI fusion biopsy systems for diagnosing prostate cancer | DG53 | | |
| Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries | IPG762 | | |
| Head injury: assessment and early management | NG232 | | |
| Risankizumab for previously treated moderately to severely active Crohn's disease | TA888 | | |
| Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA889 | | |
| Difelikefalin for treating pruritus in people having haemodialysis | TA890 | | |
| Diabetes (type 1 and type 2) in children and young people: diagnosis and management | NG18 | | |
| Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | TA886 | | |
| Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer | TA887 | | |
| Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments | TA881 | | |
| Voclosporin with mycophenolate mofetil for treating lupus nephritis | TA882 | | |
| Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma | TA883 | | |
| Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) | TA884 | | |
| Metastatic malignant disease of unknown primary origin in adults: diagnosis and management | CG104 | | |
| Tezepelumab for treating severe asthma | TA880 | | |
| Lumasiran for treating primary hyperoxaluria type 1 | HST25 | | |
| Onasemnogene abeparvovec for treating spinal muscular atrophy | HST15 | | |
| Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency | HST26 | | |
| Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy | HST24 | | |
| Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea | IPG760 | | |
| Endoscopic ultrasound-guided biliary drainage for biliary obstruction | IPG761 | | |
| Hypertension in pregnancy: diagnosis and management | NG133 | | |
| AposHealth for knee osteoarthritis | MTG76 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) | TA879 | | |
| Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases | IPG759 | | |
| Percutaneous thoracic duct embolisation for persistent chyle leak | IPG755 | | |
| Focal therapy using high-intensity focused ultrasound for localised prostate cancer | IPG756 | | |
| Maximal cytoreductive surgery for advanced ovarian cancer | IPG757 | | |
| Radiofrequency ablation for palliation of painful spinal metastases | IPG758 | | |
| UrgoStart for treating diabetic foot ulcers and leg ulcers | MTG42 | | |
| Finerenone for treating chronic kidney disease in type 2 diabetes | TA877 | | |
| Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer | TA876 | | |
| Asfotase alfa for treating paediatric-onset hypophosphatasia | HST23 | | |
| Endoluminal gastroplication for gastro-oesophageal reflux disease | IPG753 | | |
| Percutaneous transluminal renal sympathetic denervation for resistant hypertension | IPG754 | | |
| Eptinezumab for preventing migraine | TA871 | | |
| Cannabidiol for treating seizures caused by tuberous sclerosis complex | TA873 | | |
| Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma | TA874 | | |
| Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies | TA872 | | |
| Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene | HST22 | | |
| Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | TA870 | | |
| Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) | TA867 | | |
| Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) | TA869 | | |
| Vutrisiran for treating hereditary transthyretin-related amyloidosis | TA868 | | |
| Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management | NG231 | | |
| Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma | TA865 | | |
| Regorafenib for previously treated metastatic colorectal cancer | TA866 | | |
| Transvenous obliteration for gastric varices | IPG751 | | |
| Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer | IPG752 | | |
| Upadacitinib for treating active non-radiographic axial spondyloarthritis | TA861 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 | | |
| Somatrogon for treating growth disturbance in children and young people aged 3 years and over | TA863 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted | TA864 | | |
| Delirium: prevention, diagnosis and management in hospital and long-term care | CG103 | | |
| Maribavir for treating refractory cytomegalovirus infection after transplant | TA860 | | |
| Trabeculectomy with a biodegradable collagen matrix implant for glaucoma | IPG750 | | |
| Tobacco: preventing uptake, promoting quitting and treating dependence | NG209 | | |
| Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) | TA859 | | |
| Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education | NG213 | | |
| MRI-based technologies for assessing non-alcoholic fatty liver disease | DG50 | | |
| Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease | IPG749 | | |
| Transcutaneous electrical stimulation of the trigeminal nerve for ADHD | IPG748 | | |
| Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma | TA857 | | |
| Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma | TA858 | | |
| Hip fracture: management | CG124 | | |
| Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain | IPG747 | | |
| Upadacitinib for treating moderately to severely active ulcerative colitis | TA856 | | |
| Thyroid cancer: assessment and management | NG230 | | |
| Avatrombopag for treating primary chronic immune thrombocytopenia | TA853 | | |
| Fetal monitoring in labour | NG229 | | |
| Cabozantinib for previously treated advanced hepatocellular carcinoma | TA849 | | |
| Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy | TA850 | | |
| Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | TA851 | | |
| Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments | TA852 | | |
| Esketamine nasal spray for treatment-resistant depression | TA854 | | |
| Memokath 051 Ureter stent for ureteric obstruction | MTG75 | | |
| Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) | TA848 | | |
| Optilume for treating recurrent bulbar urethral strictures | MTG73 | | |
| GreenLight XPS for treating benign prostatic hyperplasia | MTG74 | | |
| Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) | TA845 | | |
| Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) | TA846 | | |
| Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA847 | | |
| Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) | TA844 | | |
| Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) | TA843 | | |
| Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis | IPG746 | | |
| Fractures (complex): assessment and management | NG37 | | |
| Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management | NG228 | | |
| Ab interno canaloplasty for open-angle glaucoma | IPG745 | | |
| Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA841 | | |
| Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) | TA842 | | |
| Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules | IPG743 | | |
| Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) | TA839 | | |
| Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids
(terminated appraisal) | TA840 | | |
| Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder | IPG742 | | |
| Advocacy services for adults with health and social care needs | NG227 | | |
| Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) | TA838 | | |
| Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine | IPG740 | | |
| YAG laser vitreolysis for symptomatic vitreous floaters | IPG741 | | |
| Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | TA837 | | |
| Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA836 | | |
| Osteoarthritis in over 16s: diagnosis and management | NG226 | | |
| Pembrolizumab for adjuvant treatment of renal cell carcinoma | TA830 | | |
| Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids | TA832 | | |
| Zanubrutinib for treating Waldenstrom's macroglobulinaemia | TA833 | | |
| Fostamatinib for treating refractory chronic immune thrombocytopenia | TA835 | | |
| SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) | TA834 | | |
| Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer | MTG72 | | |
| Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy | TA827 | | |
| Ozanimod for treating moderately to severely active ulcerative colitis | TA828 | | |
| Upadacitinib for treating active ankylosing spondylitis | TA829 | | |
| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA823 | | |
| Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain | IPG739 | | |
| Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG737 | | |
| Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause | IPG738 | | |
| Neuropad for detecting preclinical diabetic peripheral neuropathy | MTG38 | | |
| Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis | TA825 | | |
| Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) | TA826 | | |
| Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas | CG118 | | |
| Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) | TA822 | | |
| Dexamethasone intravitreal implant for treating diabetic macular oedema | TA824 | | |
| Self-harm: assessment, management and preventing recurrence | NG225 | | |
| Faecal microbiota transplant for recurrent Clostridioides difficile infection | MTG71 | | |
| Brolucizumab for treating diabetic macular oedema | TA820 | | |
| iFuse for treating chronic sacroiliac joint pain | MTG39 | | |
| Focal resurfacing implants to treat articular cartilage damage in the knee | IPG734 | | |
| Transcutaneous electrical neuromuscular stimulation for urinary incontinence | IPG735 | | |
| Superficial venous arterialisation for chronic limb threatening ischaemia | IPG736 | | |
| Avalglucosidase alfa for treating Pompe disease | TA821 | | |
| Type 1 diabetes in adults: diagnosis and management | NG17 | | |
| Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies | TA819 | | |
| Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | TA818 | | |
| SecurAcath for securing percutaneous catheters | MTG34 | | |
| Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA815 | | |
| Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | | |
| Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence | TA817 | | |
| Bioresorbable stent implantation to treat coronary artery disease | IPG732 | | |
| Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection | IPG733 | | |
| Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer | TA812 | | |
| Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors | TA813 | | |
| Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis | TA814 | | |
| PLGF-based testing to help diagnose suspected preterm pre-eclampsia | DG49 | | |
| Transcatheter tricuspid valve annuloplasty for tricuspid regurgitation | IPG730 | | |
| Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation | IPG731 | | |
| Melanoma: assessment and management | NG14 | | |
| Urinary tract infection in under 16s: diagnosis and management | NG224 | | |
| Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) | TA811 | | |
| Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease | TA809 | | |
| Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | | |
| PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites | MTG9 | | |
| Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA803 | | |
| Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides | TA805 | | |
| Belimumab for treating lupus nephritis (terminated appraisal) | TA806 | | |
| Roxadustat for treating symptomatic anaemia in chronic kidney disease | TA807 | | |
| Fenfluramine for treating seizures associated with Dravet syndrome | TA808 | | |
| Setmelanotide for treating obesity caused by LEPR or POMC deficiency | HST21 | | |
| Social, emotional and mental wellbeing in primary and secondary education | NG223 | | |
| MiraQ for assessing graft flow during coronary artery bypass graft surgery | MTG8 | | |
| Teduglutide for treating short bowel syndrome | TA804 | | |
| Vertebral body tethering for idiopathic scoliosis in children and young people | IPG728 | | |
| Nerve graft for corneal denervation | IPG729 | | |
| Depression in adults: treatment and management | NG222 | | |
| Type 2 diabetes in adults: management | NG28 | | |
| Faricimab for treating diabetic macular oedema | TA799 | | |
| Faricimab for treating wet age-related macular degeneration | TA800 | | |
| Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | TA801 | | |
| Cemiplimab for treating advanced cutaneous squamous cell carcinoma | TA802 | | |
| Multiple sclerosis in adults: management | NG220 | | |
| Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation | TA798 | | |
| Reducing sexually transmitted infections | NG221 | | |
| Venetoclax for treating chronic lymphocytic leukaemia | TA796 | | |
| Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 | | |
| Preterm labour and birth | NG25 | | |
| Gout: diagnosis and management | NG219 | | |
| Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) | TA793 | | |
| Diroximel fumarate for treating relapsing–remitting multiple sclerosis | TA794 | | |
| Ibrutinib for treating Waldenstrom's macroglobulinaemia | TA795 | | |
| Peristeen Plus transanal irrigation system for managing bowel dysfunction | MTG36 | | |
| Thopaz+ portable digital system for managing chest drains | MTG37 | | |
| Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) | IPG727 | | |
| Filgotinib for treating moderately to severely active ulcerative colitis | TA792 | | |
| Social work with adults experiencing complex needs | NG216 | | |
| Endoanchoring systems in endovascular aortic aneurysm repair | IPG725 | | |
| Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis | IPG726 | | |
| TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) | TA790 | | |
| Romosozumab for treating severe osteoporosis | TA791 | | |
| Sleepio to treat insomnia and insomnia symptoms | MTG70 | | |
| Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome | IPG724 | | |
| Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations | TA789 | | |
| Vaccine uptake in the general population | NG218 | | |
| Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy | TA788 | | |
| Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over | HST20 | | |
| Liposuction for chronic lymphoedema | IPG723 | | |
| Epilepsies in children, young people and adults | NG217 | | |
| Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies | TA786 | | |
| Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA787 | | |
| Elosulfase alfa for treating mucopolysaccharidosis type 4A | HST19 | | |
| Intramedullary distraction for upper limb lengthening | IPG722 | | |
| Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults | NG215 | | |
| Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | TA784 | | |
| Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) | TA785 | | |
| Stroke and transient ischaemic attack in over 16s: diagnosis and initial management | NG128 | | |
| Daratumumab monotherapy for treating relapsed and refractory multiple myeloma | TA783 | | |
| myCOPD for managing chronic obstructive pulmonary disease | MTG68 | | |
| UroShield for preventing catheter-associated urinary tract infections | MTG69 | | |
| Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) | DG47 | | |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer | TA781 | | |
| Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) | TA782 | | |
| Liposuction for chronic lipoedema | IPG721 | | |
| Atidarsagene autotemcel for treating metachromatic leukodystrophy | HST18 | | |
| Nivolumab with ipilimumab for untreated advanced renal cell carcinoma | TA780 | | |
| Integrated health and social care for people experiencing homelessness | NG214 | | |
| Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA779 | | |
| Otitis media (acute): antimicrobial prescribing | NG91 | | |
| Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis | IPG720 | | |
| Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA774 | | |
| Empagliflozin for treating chronic heart failure with reduced ejection fraction | TA773 | | |
| Dapagliflozin for treating chronic kidney disease | TA775 | | |
| Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA776 | | |
| Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA777 | | |
| Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria | TA778 | | |
| Prontosan for treating acute and chronic wounds | MTG67 | | |
| 3C Patch for treating diabetic foot ulcers | MTG66 | | |
| Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach | IPG717 | | |
| Intramedullary distraction for lower limb lengthening | IPG718 | | |
| Endoscopic balloon dilation for subglottic or tracheal stenosis | IPG719 | | |
| Mental wellbeing at work | NG212 | | |
| PredictSURE IBD and IBDX to guide treatment of Crohn's disease | DG45 | | |
| EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules | DG46 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies | TA772 | | |
| Odevixibat for treating progressive familial intrahepatic cholestasis | HST17 | | |
| Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer | TA770 | | |
| Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) | TA771 | | |
| Stereotactic radiosurgery for trigeminal neuralgia | IPG715 | | |
| Microwave ablation for primary or metastatic cancer in the lung | IPG716 | | |
| Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) | TA762 | | |
| Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable | TA763 | | |
| Fremanezumab for preventing migraine | TA764 | | |
| Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA765 | | |
| Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma | TA766 | | |
| Ponesimod for treating relapsing–remitting multiple sclerosis | TA767 | | |
| Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA768 | | |
| Palforzia for treating peanut allergy in children and young people | TA769 | | |
| Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care | MTG65 | | |
| Glaucoma: diagnosis and management | NG81 | | |
| Sodium zirconium cyclosilicate for treating hyperkalaemia | TA599 | | |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA761 | | |
| Rehabilitation after traumatic injury | NG211 | | |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA760 | | |
| Cabotegravir with rilpivirine for treating HIV-1 | TA757 | | |
| Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy | TA758 | | |
| Headaches in over 12s: diagnosis and management | CG150 | | |
| Endo-SPONGE for treating low rectal anastomotic leak | MTG63 | | |
| Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA756 | | |
| Transanal total mesorectal excision for rectal cancer | IPG713 | | |
| Endobronchial nerve ablation for chronic obstructive pulmonary disease | IPG714 | | |
| Colorectal cancer | NG151 | | |
| Prostate cancer: diagnosis and management | NG131 | | |
| Belimumab for treating active autoantibody-positive systemic lupus erythematosus | TA752 | | |
| Cenobamate for treating focal onset seizures in epilepsy | TA753 | | |
| Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome | TA754 | | |
| ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections | MTG62 | | |
| Pelvic floor dysfunction: prevention and non-surgical management | NG210 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) | TA750 | | |
| Dupilumab for treating severe asthma with type 2 inflammation | TA751 | | |
| Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders | TA748 | | |
| Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) | TA749 | | |
| Synergo for non-muscle-invasive bladder cancer | MTG61 | | |
| Fever in under 5s: assessment and initial management | NG143 | | |
| Givosiran for treating acute hepatic porphyria | HST16 | | |
| Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure | IPG711 | | |
| Coronary sinus narrowing device implantation for refractory angina | IPG712 | | |
| Chronic kidney disease: assessment and management | NG203 | | |
| SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea | DG44 | | |
| Acute heart failure: diagnosis and management | CG187 | | |
| Heart valve disease presenting in adults: investigation and management | NG208 | | |
| Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer | TA746 | | |
| Nintedanib for treating progressive fibrosing interstitial lung diseases | TA747 | | |
| Upadacitinib for treating moderate rheumatoid arthritis | TA744 | | |
| NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) | TA745 | | |
| Inducing labour | NG207 | | |
| Selpercatinib for treating advanced thyroid cancer with RET alterations | TA742 | | |
| Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management | NG206 | | |
| Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | TA740 | | |
| Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA741 | | |
| Genicular artery embolisation for pain from knee osteoarthritis | IPG708 | | |
| Laparoscopic renal denervation for loin pain haematuria syndrome | IPG709 | | |
| Percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access | IPG710 | | |
| Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable | TA739 | | |
| Looked-after children and young people | NG205 | | |
| Tofacitinib for treating juvenile idiopathic arthritis | TA735 | | |
| Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy | TA736 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer | TA737 | | |
| Berotralstat for preventing recurrent attacks of hereditary angioedema | TA738 | | |
| Secukinumab for treating moderate to severe plaque psoriasis in children and young people | TA734 | | |
| Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) | TA732 | | |
| Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA733 | | |
| DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography | MTG60 | | |
| Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) | TA730 | | |
| Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) | TA731 | | |
| Lateral elbow resurfacing for arthritis | IPG705 | | |
| Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis | IPG706 | | |
| Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair | IPG707 | | |
| Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA726 | | |
| Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA727 | | |
| Midostaurin for treating advanced systemic mastocytosis | TA728 | | |
| Sapropterin for treating hyperphenylalaninaemia in phenylketonuria | TA729 | | |
| Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | | |
| Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer | TA724 | | |
| Bimekizumab for treating moderate to severe plaque psoriasis | TA723 | | |
| Magnetic resonance therapy for knee osteoarthritis | IPG702 | | |
| Laparoscopic removal of uterine fibroids with power morcellation | IPG703 | | |
| Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids | IPG704 | | |
| Babies, children and young people's experience of healthcare | NG204 | | |
| Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA722 | | |
| Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s | NG202 | | |
| Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome | TA139 | | |
| Antenatal care | NG201 | | |
| Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | TA720 | | |
| Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | | |
| Bronchiolitis in children: diagnosis and management | NG9 | | |
| Inducing and maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage | IPG701 | | |
| Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA716 | | |
| Clostridioides difficile infection: antimicrobial prescribing | NG199 | | |
| ENDURALIFE powered CRT-D devices for treating heart failure | MTG33 | | |
| Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) | TA717 | | |
| Ixekizumab for treating axial spondyloarthritis | TA718 | | |
| Secukinumab for treating non-radiographic axial spondyloarthritis | TA719 | | |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA714 | | |
| Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | | |
| Enzalutamide for treating hormone-sensitive metastatic prostate cancer | TA712 | | |
| Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy | TA713 | | |
| Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA275 | | |
| Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation | TA249 | | |
| Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation | TA256 | | |
| Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA355 | | |
| Atrial fibrillation: diagnosis and management | NG196 | | |
| Plus Sutures for preventing surgical site infection | MTG59 | | |
| Laser lithotripsy for difficult-to-treat bile duct stones | IPG699 | | |
| Percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve | IPG700 | | |
| Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis | TA708 | | |
| Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA709 | | |
| Ravulizumab for treating atypical haemolytic uraemic syndrome | TA710 | | |
| Patient experience in adult NHS services: improving the experience of care for people using adult NHS services | CG138 | | |
| Shared decision making | NG197 | | |
| Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer | TA707 | | |
| Autism spectrum disorder in adults: diagnosis and management | CG142 | | |
| Autism spectrum disorder in under 19s: support and management | CG170 | | |
| Ozanimod for treating relapsing–remitting multiple sclerosis | TA706 | | |
| Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer | TA705 | | |
| Electrohydraulic lithotripsy for difficult-to-treat bile duct stones | IPG698 | | |
| Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant | IPG695 | | |
| Transvaginal laser therapy for stress urinary incontinence | IPG696 | | |
| Transvaginal laser therapy for urogenital atrophy | IPG697 | | |
| Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) | TA702 | | |
| Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) | TA703 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | TA704 | | |
| Heavy menstrual bleeding: assessment and management | NG88 | | |
| HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography | MTG32 | | |
| Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers | MTG20 | | |
| Ravulizumab for treating paroxysmal nocturnal haemoglobinuria | TA698 | | |
| Ofatumumab for treating relapsing multiple sclerosis | TA699 | | |
| Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) | TA700 | | |
| Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) | TA701 | | |
| Tafamidis for treating transthyretin amyloidosis with cardiomyopathy | TA696 | | |
| Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban | TA697 | | |
| Permanent His-bundle pacemaker implantation for treating heart failure | IPG694 | | |
| UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia | MTG58 | | |
| Repetitive short-pulse transscleral cyclophotocoagulation for glaucoma | IPG692 | | |
| Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults | IPG693 | | |
| Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA692 | | |
| Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA694 | | |
| Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma | TA695 | | |
| Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver | IPG691 | | |
| Avelumab for treating metastatic Merkel cell carcinoma | TA517 | | |
| Acalabrutinib for treating chronic lymphocytic leukaemia | TA689 | | |
| Avelumab for untreated metastatic Merkel cell carcinoma | TA691 | | |
| Postnatal care | NG194 | | |
| Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain | NG193 | | |
| Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids | IPG689 | | |
| Extracorporeal whole liver perfusion for acute liver failure | IPG690 | | |
| Danis stent for acute oesophageal variceal bleeding | MTG57 | | |
| Anakinra for treating Still's disease | TA685 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA686 | | |
| Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA687 | | |
| Selective internal radiation therapies for treating hepatocellular carcinoma | TA688 | | |
| Cannabis-based medicinal products | NG144 | | |
| Asthma: diagnosis, monitoring and chronic asthma management | NG80 | | |
| QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography | DG43 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease | TA684 | | |
| Erenumab for preventing migraine | TA682 | | |
| Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer | TA683 | | |
| Alpha-Stim AID for anxiety disorders | MTG56 | | |
| Free-functioning gracilis transfer to restore upper limb function in brachial plexus injury | IPG687 | | |
| Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis | IPG688 | | |
| Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma | TA680 | | |
| Baricitinib for treating moderate to severe atopic dermatitis | TA681 | | |
| Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing | NG190 | | |
| Safeguarding adults in care homes | NG189 | | |
| Metreleptin for treating lipodystrophy | HST14 | | |
| Filgotinib for treating moderate to severe rheumatoid arthritis | TA676 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma | TA677 | | |
| Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA678 | | |
| Dapagliflozin for treating chronic heart failure with reduced ejection fraction | TA679 | | |
| Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA673 | | |
| Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) | TA674 | | |
| Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) | TA675 | | |
| Trabectedin for the treatment of advanced soft tissue sarcoma | TA185 | | |
| Leukomed Sorbact for preventing surgical site infection | MTG55 | | |
| Mepolizumab for treating severe eosinophilic asthma | TA671 | | |
| Brolucizumab for treating wet age-related macular degeneration | TA672 | | |
| Brain tumours (primary) and brain metastases in over 16s | NG99 | | |
| Self-expanding implant insertion into the intersphincteric space for faecal incontinence | IPG685 | | |
| Minimally invasive radical hysterectomy for early stage cervical cancer | IPG686 | | |
| The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal | MTG54 | | |
| Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor | TA670 | | |
| The PLASMA system for transurethral resection and haemostasis of the prostate | MTG53 | | |
| Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer | TA668 | | |
| Pancreatitis | NG104 | | |
| Diabetes in pregnancy: management from preconception to the postnatal period | NG3 | | |
| Eating disorders: recognition and treatment | NG69 | | |
| Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma | TA666 | | |
| Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura | TA667 | | |
| Peripheral arterial disease: diagnosis and management | CG147 | | |
| Low back pain and sciatica in over 16s: assessment and management | NG59 | | |
| Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia | TA663 | | |
| Liraglutide for managing overweight and obesity | TA664 | | |
| Upadacitinib for treating severe rheumatoid arthritis | TA665 | | |
| Zio XT for detecting cardiac arrhythmias | MTG52 | | |
| Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer | TA660 | | |
| Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma | TA661 | | |
| Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) | TA662 | | |
| Swallowable gastric balloon capsule for weight loss | IPG684 | | |
| Acute coronary syndromes | NG185 | | |
| Drug-eluting stents for the treatment of coronary artery disease | TA152 | | |
| Guidance on the use of coronary artery stents | TA71 | | |
| Siponimod for treating secondary progressive multiple sclerosis | TA656 | | |
| Carfilzomib for previously treated multiple myeloma | TA657 | | |
| Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma | TA658 | | |
| Galcanezumab for preventing migraine | TA659 | | |
| Human and animal bites: antimicrobial prescribing | NG184 | | |
| Testing strategies for Lynch syndrome in people with endometrial cancer | DG42 | | |
| Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis | IPG681 | | |
| Balloon cryoablation for Barrett's oesophagus | IPG682 | | |
| Balloon cryoablation for squamous dysplasia of the oesophagus | IPG683 | | |
| Volanesorsen for treating familial chylomicronaemia syndrome | HST13 | | |
| Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy | TA655 | | |
| SEM Scanner 200 for preventing pressure ulcers | MTG51 | | |
| Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer | TA653 | | |
| Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA654 | | |
| Rheumatoid arthritis in adults: management | NG100 | | |
| Behaviour change: digital and mobile health interventions | NG183 | | |
| Pembrolizumab with axitinib for untreated advanced renal cell carcinoma | TA650 | | |
| Naldemedine for treating opioid-induced constipation | TA651 | | |
| Transcranial magnetic stimulation for auditory hallucinations | IPG680 | | |
| Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma | TA649 | | |
| Neuropathic pain in adults: pharmacological management in non-specialist settings | CG173 | | |
| Insect bites and stings: antimicrobial prescribing | NG182 | | |
| Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA648 | | |
| Axonics sacral neuromodulation system for treating refractory overactive bladder | MTG50 | | |
| Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke | DG41 | | |
| Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) | TA646 | | |
| Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) | TA647 | | |
| Avelumab with axitinib for untreated advanced renal cell carcinoma | TA645 | | |
| High-sensitivity troponin tests for the early rule out of NSTEMI | DG40 | | |
| Anaphylaxis: assessment and referral after emergency treatment | CG134 | | |
| Perioperative care in adults | NG180 | | |
| Rehabilitation for adults with complex psychosis | NG181 | | |
| Surgical site infections: prevention and treatment | NG125 | | |
| Deep brain stimulation for refractory epilepsy in adults | IPG678 | | |
| Implanted vagus nerve stimulation for treatment-resistant depression | IPG679 | | |
| Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma | TA641 | | |
| Gilteritinib for treating relapsed or refractory acute myeloid leukaemia | TA642 | | |
| Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer | TA643 | | |
| Entrectinib for treating NTRK fusion-positive solid tumours | TA644 | | |
| Transcranial magnetic stimulation for obsessive-compulsive disorder | IPG676 | | |
| Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease | IPG677 | | |
| Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant | TA640 | | |
| Artificial iris insertion for acquired aniridia | IPG674 | | |
| Artificial iris insertion for congenital aniridia | IPG675 | | |
| Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | TA638 | | |
| Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | TA639 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA634 | | |
| Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) | TA635 | | |
| Eculizumab for treating refractory myasthenia gravis (terminated appraisal) | TA636 | | |
| Ranibizumab for treating diabetic retinopathy (terminated appraisal) | TA637 | | |
| Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention | IPG673 | | |
| Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia | MTG49 | | |
| Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA626 | | |
| Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) | DG39 | | |
| Ustekinumab for treating moderately to severely active ulcerative colitis | TA633 | | |
| Generalised anxiety disorder and panic disorder in adults: management | CG113 | | |
| Intravenous fluid therapy in children and young people in hospital | NG29 | | |
| Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer | TA632 | | |
| Joint replacement (primary): hip, knee and shoulder | NG157 | | |
| Larotrectinib for treating NTRK fusion-positive solid tumours | TA630 | | |
| Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer | TA628 | | |
| Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab | TA629 | | |
| PneuX to prevent ventilator-associated pneumonia | MTG48 | | |
| Lenalidomide with rituximab for previously treated follicular lymphoma | TA627 | | |
| Abdominal aortic aneurysm: diagnosis and management | NG156 | | |
| Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis | TA312 | | |
| Tinnitus: assessment and management | NG155 | | |
| Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse | IPG669 | | |
| Cyanoacrylate glue occlusion for varicose veins | IPG670 | | |
| MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy | IPG671 | | |
| Selective internal radiation therapy for unresectable colorectal metastases in the liver | IPG672 | | |
| Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) | TA625 | | |
| Impetigo: antimicrobial prescribing | NG153 | | |
| Neonatal parenteral nutrition | NG154 | | |
| SepsiTest assay for rapidly identifying bloodstream bacteria and fungi | DG20 | | |
| Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis | TA624 | | |
| Patiromer for treating hyperkalaemia | TA623 | | |
| Sotagliflozin with insulin for treating type 1 diabetes | TA622 | | |
| Antenatal and postnatal mental health: clinical management and service guidance | CG192 | | |
| Episcissors-60 for mediolateral episiotomy | MTG47 | | |
| Leg ulcer infection: antimicrobial prescribing | NG152 | | |
| Fetoscopic prenatal repair for open neural tube defects in the fetus | IPG667 | | |
| Open prenatal repair for open neural tube defects in the fetus | IPG668 | | |
| Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues | IPG666 | | |
| Supporting adult carers | NG150 | | |
| Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C | MTG27 | | |
| Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) | TA618 | | |
| Indoor air quality at home | NG149 | | |
| Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA617 | | |
| Cladribine for treating relapsing–remitting multiple sclerosis | TA616 | | |
| Balloon dilation for chronic eustachian tube dysfunction | IPG665 | | |
| Cannabidiol with clobazam for treating seizures associated with Dravet syndrome | TA614 | | |
| Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome | TA615 | | |
| Menopause: diagnosis and management | NG23 | | |
| gammaCore for cluster headache | MTG46 | | |
| Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 | HST12 | | |
| Irreversible electroporation for primary liver cancer | IPG664 | | |
| Diverticular disease: diagnosis and management | NG147 | | |
| Workplace health: long-term sickness absence and capability to work | NG146 | | |
| Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab | TA612 | | |
| Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast | DG37 | | |
| Rapid tests for group A streptococcal infections in people with a sore throat | DG38 | | |
| Pentosan polysulfate sodium for treating bladder pain syndrome | TA610 | | |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | TA611 | | |
| Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) | TA608 | | |
| Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) | TA609 | | |
| Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management | CG184 | | |
| Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease | TA607 | | |
| Midcarpal hemiarthroplasty for wrist arthritis | IPG663 | | |
| End of life care for adults: service delivery | NG142 | | |
| Lanadelumab for preventing recurrent attacks of hereditary angioedema | TA606 | | |
| Diabetic foot problems: prevention and management | NG19 | | |
| Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations | HST11 | | |
| Gastro-oesophageal reflux disease in children and young people: diagnosis and management | NG1 | | |
| Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea | TA605 | | |
| EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing | MTG12 | | |
| Familial hypercholesterolaemia: identification and management | CG71 | | |
| Idelalisib for treating refractory follicular lymphoma | TA604 | | |
| Cellulitis and erysipelas: antimicrobial prescribing | NG141 | | |
| High-intensity focused ultrasound for glaucoma | IPG661 | | |
| Bioprosthetic plug insertion for anal fistula | IPG662 | | |
| Abortion care | NG140 | | |
| Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA602 | | |
| Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA603 | | |
| Tegaderm CHG securement dressing for vascular access sites in critically ill adults | MTG25 | | |
| Pneumonia (community-acquired): antimicrobial prescribing | NG138 | | |
| Pneumonia (hospital-acquired): antimicrobial prescribing | NG139 | | |
| Attention deficit hyperactivity disorder: diagnosis and management | NG87 | | |
| Implant insertion for prominent ears | IPG660 | | |
| Benralizumab for treating severe eosinophilic asthma | TA565 | | |
| Risankizumab for treating moderate to severe plaque psoriasis | TA596 | | |
| Patisiran for treating hereditary transthyretin amyloidosis | HST10 | | |
| Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms | IPG658 | | |
| Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer | IPG659 | | |
| Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) | TA594 | | |
| Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA595 | | |
| Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism | NG89 | | |
| Alcohol interventions in secondary and further education | NG135 | | |
| PICO negative pressure wound dressings for closed surgical incisions | MTG43 | | |
| Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis | TA590 | | |
| Letermovir for preventing cytomegalovirus disease after a stem cell transplant | TA591 | | |
| Chronic obstructive pulmonary disease in over 16s: diagnosis and management | NG115 | | |
| End of life care for infants, children and young people with life-limiting conditions: planning and management | NG61 | | |
| Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer | IPG656 | | |
| Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids | IPG657 | | |
| Nusinersen for treating spinal muscular atrophy | TA588 | | |
| Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity | TA589 | | |
| Motor neurone disease: assessment and management | NG42 | | |
| Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis | DG36 | | |
| Bisphosphonates for treating osteoporosis | TA464 | | |
| Long-acting reversible contraception | CG30 | | |
| Cardiac contractility modulation device implantation for heart failure | IPG655 | | |
| Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction | IPG653 | | |
| Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia | IPG654 | | |
| Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality | TA322 | | |
| Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies | TA171 | | |
| Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib | TA586 | | |
| Lenalidomide plus dexamethasone for previously untreated multiple myeloma | TA587 | | |
| Depression in children and young people: identification and management | NG134 | | |
| Urinary incontinence and pelvic organ prolapse in women: management | NG123 | | |
| Ambu aScope4 Broncho for use in unexpected difficult airways | MTG14 | | |
| Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI | IPG650 | | |
| Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg | IPG651 | | |
| Bronchoscopic thermal vapour ablation for upper-lobe emphysema | IPG652 | | |
| Ocrelizumab for treating primary progressive multiple sclerosis | TA585 | | |
| Endocuff Vision for assisting visualisation during colonoscopy | MTG45 | | |
| Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes | TA583 | | |
| Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer | TA584 | | |
| The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters | MTG24 | | |
| Therapeutic hypothermia for acute ischaemic stroke | IPG647 | | |
| Collagen paste for closing an anal fistula | IPG648 | | |
| Percutaneous mitral valve leaflet repair for mitral regurgitation | IPG649 | | |
| Hyperparathyroidism (primary): diagnosis, assessment and initial management | NG132 | | |
| Inotersen for treating hereditary transthyretin amyloidosis | HST9 | | |
| Enzalutamide for hormone-relapsed non-metastatic prostate cancer | TA580 | | |
| Curos for preventing infections when using needleless connectors | MTG44 | | |
| Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care | DG35 | | |
| Crohn's disease: management | NG129 | | |
| Ulcerative colitis: management | NG130 | | |
| Intrapartum care for women with existing medical conditions or obstetric complications and their babies | NG121 | | |
| Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma | TA577 | | |
| Endoscopic ablation for an anal fistula | IPG645 | | |
| Endoscopic ablation for a pilonidal sinus | IPG646 | | |
| Certolizumab pegol for treating moderate to severe plaque psoriasis | TA574 | | |
| Tildrakizumab for treating moderate to severe plaque psoriasis | TA575 | | |
| Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) | TA576 | | |
| Specialist neonatal respiratory care for babies born preterm | NG124 | | |
| Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes | TA572 | | |
| The Debrisoft monofilament debridement pad for use in acute or chronic wounds | MTG17 | | |
| Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib | TA571 | | |
| Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) | TA570 | | |
| Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer | TA569 | | |
| Radially emitting laser fibre treatment of an anal fistula | IPG644 | | |
| Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) | TA568 | | |
| Cochlear implants for children and adults with severe to profound deafness | TA566 | | |
| High-intensity focused ultrasound for symptomatic benign thyroid nodules | IPG643 | | |
| Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia | TA561 | | |
| Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma | TA562 | | |
| Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA563 | | |
| Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal | IPG642 | | |
| Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) | TA560 | | |
| Cough (acute): antimicrobial prescribing | NG120 | | |
| Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer | IPG638 | | |
| Laparoscopic cerclage for cervical incompetence to prevent late miscarriage or preterm birth | IPG639 | | |
| Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis | IPG640 | | |
| Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain | MTG41 | | |
| Platelet-rich plasma injections for knee osteoarthritis | IPG637 | | |
| Ex-situ machine perfusion for extracorporeal preservation of livers for transplantation | IPG636 | | |
| Cerebral palsy in adults | NG119 | | |
| Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers | MTG40 | | |
| Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms | MTG10 | | |
| Regorafenib for previously treated advanced hepatocellular carcinoma | TA555 | | |
| Darvadstrocel for treating complex perianal fistulas in Crohn's disease | TA556 | | |
| Renal and ureteric stones: assessment and management | NG118 | | |
| Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years | TA554 | | |
| Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer | DG34 | | |
| Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults | IPG634 | | |
| Bronchial thermoplasty for severe asthma | IPG635 | | |
| Lenvatinib for untreated advanced hepatocellular carcinoma | TA551 | | |
| Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia | TA552 | | |
| Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing | NG117 | | |
| Vandetanib for treating medullary thyroid cancer | TA550 | | |
| Post-traumatic stress disorder | NG116 | | |
| Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing | NG114 | | |
| Decitabine for untreated acute myeloid leukaemia (terminated appraisal) | TA548 | | |
| Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) | TA549 | | |
| Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain | IPG632 | | |
| Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions | IPG633 | | |
| Tofacitinib for moderately to severely active ulcerative colitis | TA547 | | |
| Urinary tract infection (catheter-associated): antimicrobial prescribing | NG113 | | |
| Padeliporfin for untreated localised prostate cancer | TA546 | | |
| Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis | IPG631 | | |
| Gemtuzumab ozogamicin for untreated acute myeloid leukaemia | TA545 | | |
| Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma | IPG630 | | |
| Urinary tract infection (lower): antimicrobial prescribing | NG109 | | |
| Prostatitis (acute): antimicrobial prescribing | NG110 | | |
| Pyelonephritis (acute): antimicrobial prescribing | NG111 | | |
| Urinary tract infection (recurrent): antimicrobial prescribing | NG112 | | |
| Eltrombopag for treating chronic immune thrombocytopenia | TA293 | | |
| Romiplostim for the treatment of chronic immune thrombocytopenia | TA221 | | |
| Myeloma: diagnosis and management | NG35 | | |
| Lyme disease | NG95 | | |
| Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma | TA544 | | |
| Burosumab for treating X-linked hypophosphataemia in children and young people | HST8 | | |
| Renal replacement therapy and conservative management | NG107 | | |
| Decision-making and mental capacity | NG108 | | |
| Cabozantinib for untreated advanced renal cell carcinoma | TA542 | | |
| Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA543 | | |
| E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta | MTG16 | | |
| Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer | IPG628 | | |
| Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia | TA541 | | |
| Chronic heart failure in adults: diagnosis and management | NG106 | | |
| Preventing suicide in community and custodial settings | NG105 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma | TA540 | | |
| Leadless cardiac pacemaker implantation for bradyarrhythmias | IPG626 | | |
| Superior rectal artery embolisation for haemorrhoids | IPG627 | | |
| Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours | TA539 | | |
| Sutureless aortic valve replacement for aortic stenosis | IPG624 | | |
| Flu vaccination: increasing uptake | NG103 | | |
| Dinutuximab beta for treating neuroblastoma | TA538 | | |
| Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG625 | | |
| Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine | TA535 | | |
| Alectinib for untreated ALK-positive advanced non-small-cell lung cancer | TA536 | | |
| Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA537 | | |
| Community pharmacies: promoting health and wellbeing | NG102 | | |
| Dupilumab for treating moderate to severe atopic dermatitis | TA534 | | |
| Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing | IPG621 | | |
| Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing | IPG622 | | |
| Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures | IPG623 | | |
| Superior capsular augmentation for massive rotator cuff tears | IPG619 | | |
| Transaxial interbody lumbosacral fusion for severe chronic low back pain | IPG620 | | |
| Ocrelizumab for treating relapsing–remitting multiple sclerosis | TA533 | | |
| Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer | TA531 | | |
| Biomarker tests to help diagnose preterm labour in women with intact membranes | DG33 | | |
| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | TA529 | | |
| Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy | TA530 | | |
| Beta interferons and glatiramer acetate for treating multiple sclerosis | TA527 | | |
| Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor | IPG617 | | |
| Laparoscopic ventral mesh rectopexy for internal rectal prolapse | IPG618 | | |
| Dementia: assessment, management and support for people living with dementia and their carers | NG97 | | |
| Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | TA217 | | |
| Intranasal phototherapy for allergic rhinitis | IPG616 | | |
| Guselkumab for treating moderate to severe plaque psoriasis | TA521 | | |
| Midostaurin for untreated acute myeloid leukaemia | TA523 | | |
| Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma | TA524 | | |
| Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA525 | | |
| Arsenic trioxide for treating acute promyelocytic leukaemia | TA526 | | |
| Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over | NG36 | | |
| Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer | IPG614 | | |
| Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy | IPG615 | | |
| Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy | TA520 | | |
| Percutaneous balloon valvuloplasty for fetal critical aortic stenosis | IPG613 | | |
| Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I | DG32 | | |
| Robot-assisted kidney transplant | IPG609 | | |
| Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG611 | | |
| Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma | IPG612 | | |
| Nerve transfer to partially restore upper limb function in tetraplegia | IPG610 | | |
| Tocilizumab for treating giant cell arteritis | TA518 | | |
| Care and support of people growing older with learning disabilities | NG96 | | |